ClinicalTrials.gg
CompletedNCT01479127Updated Apr 21, 2016Results posted

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

A Phase 2 interventional study of ABT-SLV187 and Oral Levodopa/Carbidopa in Advanced Parkinson's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 30 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-04-21.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 99 Years
Sex
All
01

Study summary

To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced Parkinson's disease (PD) patients with severe motor complications. The complications of medical devices for the naso-jejunum (NJ) infusion system of ABT-SLV187 will also be investigated.

02

Conditions studied

  • Advanced Parkinson's Disease

Browse trials for

Keywords

  • Levodopa-carbidopa intestinal gel
  • Advanced Parkinson's disease
  • Severe motor fluctuations
  • Dyskinesia
03

In context

Dyskinesias

179 studies on the registry are indexed under Dyskinesias; 24 are open to participants now.

This study's enrollment of 8 is below the median of 36 across 139 interventional studies indexed under Dyskinesias.

Browse Dyskinesias studies →

Lead sponsor

AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic PD according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank criteria
  • PD stage corresponds to 4 or 5 in the 'off' state according to the modified Hoehn \& Yahr (H \& Y) classification of disease severity
  • Levodopa-responsive subjects demonstrate some identifiable 'ON response' established by observation by Investigator and demonstrate severe motor fluctuations in spite of individually optimized treatment and where therapy options are indicated

Exclusion criteria

Exclusion Criteria:

  • Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism
  • Undergone surgery for the treatment of PD
  • to levodopa
  • Subjects with any neurological deficit that may interfere with the study assessments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Levodopa-carbidopa intestinal gel

    Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks. The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms.

    Drug: ABT-SLV187 · Drug: Oral Levodopa/Carbidopa · Device: Infusion Pump: CADD-Legacy® 1400 Pump · Device: NJ-Tube: Silicon ED Tube · Device: Adaptor: Hakko Adaptor

Interventions

  • DrugABT-SLV187

    Also known as: DUOPA™ (carbidopa and levodopa Enteral Suspension), DUODOPA®, Levodopa-carbidopa intestinal gel (LCIG)

  • DrugOral Levodopa/Carbidopa

    Drug pages: Levodopa · Carbidopa

    Tablet; contains 100 mg levodopa and 10 mg carbidopa

  • DeviceInfusion Pump: CADD-Legacy® 1400 Pump

    General infusion pump, manufactured by Smiths Medical (US)

  • DeviceNJ-Tube: Silicon ED Tube

    Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)

  • DeviceAdaptor: Hakko Adaptor

    Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period

    AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.

    Time frame: During the Run-in period (up to approximately 28 days)

  2. Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation During the ABT-SLV187 Treatment Period

    AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.

    Time frame: From NJ placement to end of ABT-SLV187 Treatment Period (Day 21) +30 days

  3. Number of Participants With Potentially Clinically Significant (PCS) Hematology Results During the ABT-SLV187 Treatment Period

    M=male, F=female, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  4. Number of Participants With PCS Blood Biochemistry Results During the ABT-SLV187 Treatment Period

    M=male, F=female, γ-GTP=gamma-glutamyl transpeptidase.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  5. Number of Participants With PCS Values in Special Laboratory Parameters During the ABT-SLV187 Treatment Period

    M=male, F=female

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  6. Number of Participants With Potentially Clinically Significant Urinalysis Results During the ABT-SLV187 Treatment Period

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  7. Number of Participants With Potentially Clinically Significant (PCS) Vital Signs Results During the ABT-SLV187 Treatment Period

    ↓=decrease, ↑=increase, BL=baseline, temp.=temperature, SBP=systolic blood pressure, Sup.=supine, Sta.=standing, DBP=diastolic blood pressure.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  8. Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period

    High potentially clinically significant Bazett's heart rate-corrected QT interval (QTcB) values were: 450 msec for males / 470 msec for females.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  9. Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "Normal" State on the Treatment Response Scale (TRS) I

    Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and Treatment Response Scale (TRS) under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia. The average of the neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia") on the TRS I (total 10 assessments per day).

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Secondary outcomes

  1. Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "OFF" and "Dyskinesia" States on the TRS I and the "Normal," "OFF," and "Dyskinesia" States on the TRS II

    Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and TRS under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia for TRS I, with the addition of Tremor at Rest and Postural Stability for TRS II. The average of the 3 neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia"), the "Off" state ("moderate OFF" to "severe OFF"), and the "Dyskinesia" state ("ON with moderate dyskinesia" to "ON with severe dyskinesia") on the TRS I or II.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  2. Change From Baseline to the End of Treatment in Parkinson's Disease Diary Assessment

    For each half hour period during 3 consecutive days prior to each assessment of the diary, participants (and/or their caregivers) entered into a diary whether they were asleep, in the ON motor state or in the OFF motor state in the following 5 grades: asleep, OFF, ON (no dyskinesia \[D\]), ON with non-troublesome dyskinesia (NTD), ON with troublesome dyskinesia (TD). ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug. Dyskinetic time is time with involuntary muscle movement. The ON or OFF times were calculated as the average of 3 daily times from the diaries. w/o = without, w/ = with

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  3. Baseline and Endpoint (End of Treatment) Video Scoring of Unified Parkinson's Disease Rating Scale (UPDRS) Items and Dyskinesia

    Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the video under blinded conditions using the following assessments: Tremor at Rest (UPDRS item #20), Finger Taps (UPDRS #23), Rapid Alternating Movement of Hands (UPDRS #25), Arising from Chair (UPDRS #27), Gait (UPDRS #29), Postural Stability (UPDRS #30), Body Bradykinesia and Hypokinesia (UPDRS #31), and Dyskinesia (evaluated with the Goetz Dyskinesia Rating Scale). The UPDRS score is the sum of the answers to individual questions, each of which are measured on a 5-point scale (0-4), with higher scores associated with more disability. The Goetz Dyskinesia Rating Scale is a 5-point scale of the severity of dyskinesias, from 0 (absent) to 4 (violent dyskinesias).

    Time frame: Baseline (Day -1), Endpoint (Day 21)

  4. Mean Change From Baseline to the End of Treatment in UPDRS Total Scores and Subscores

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score ranges from 0-176, with 176 representing the worst (total) disability, and 0 no disability. The Part I Score is the sum of the answers to the 4 questions related to Mentation, Behavior and Mood, and ranges from 0-16. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. The Part IV Score is the sum of the answers to the 11 questions related to Complications of Therapy, and ranges from 0-23. The Part IV dyskinesia subscore ranges from 0-12. For each part of the UPDRS, higher scores are associated with more disability.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  5. Change From Baseline to the End of Treatment in the Japanese Version of Parkinson's Disease Questionnaire 39 (PDQ-39) Total Score and Domain Scores

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients, including Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort, as well as a Summary Index Total Score. Scores for each are on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  6. Modified Hoehn and Yahr Staging at Baseline and End of Treatment

    Participant's ON and OFF states staged according to the Modified Hoehn and Yahr criteria, an 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  7. Schwab and England Activities of Daily Living Scale at Baseline and End of Treatment

    The Schwab and England scale was used to rate the subject's activities of daily living by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%).

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  8. Clinical Global Impression - Severity (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Baseline and End of Treatment

    The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, and among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  9. Time to Reach Peak Plasma Concentration (Tmax) After Administration of Oral Levodopa/Carbidopa (L/C) Tablets and Intra-jejunal Administration of ABT-SLV187

    Tmax of levodopa, carbidopa, and its metabolite 3-O-methyldopa (3-OMD) after administration of oral L/C tablets and intra-jejunal administration of ABT-SLV187.

    Time frame: Baseline (Day -1): pre-dose; 15, 30, 45, 60 mins post-morning dose; every 30 mins thereafter for 12 hrs. Day 21: pre-dose; 15, 30, 45, 60 mins post-infusion; every 30 mins from hrs 1 to 12 post-infusion; every 2 hrs from 12 to 16 hrs post-infusion.

  10. Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), Trough Plasma Concentration (Cmin), and Cmin Within 2 and 12 Hours (Cmin [2-12 Hours]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

    Cmax, Cavg, Cmin, and Cmin (2-12 hours) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). Cmin values for levodopa and carbidopa during the 16 hours of infusion were observed either at time 0 or 15 min after start of the infusion and were a result of drug washout prior to establishment of infusion.

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  11. The Area Under the Concentrations-time Curve From 0 to 12 and 0 to 16 Hours (AUC0-12, AUC0-16) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

    AUC0-12 and AUC0-16 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  12. AUC0-12/Dose0-12, AUC0-16/Dose0-16 After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

    AUC0-12/Dose0-12 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). AUC0-16/Dose0-16 of levodopa, carbidopa, and 3-OMD after administration of intra-jejunal administration of ABT-SLV187 (Day 21).

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  13. Degree of Fluctuation (2-12 Hours) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

    Degree of Fluctuation (calculated as \[Cmax - Cmin\] / Cavg)) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  14. Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

    M/P (AUC0-12) after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

  15. Number of Participants With Product Quality Complaints (PQC) During the ABT-SLV187 Treatment Period

    Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

07

Results

Posted Mar 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneLevodopa-carbidopa Intestinal Gel
Started8
Started lcig6
Completed5
Not completed3

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period

AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.

Time frame:
During the Run-in period (up to approximately 28 days)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period
participantsOral Levodopa/Carbidopa Tablet
AE7
AE at least possibly related to study drug/device5
Severe AE0
SAE0
AE leading to discontinuation of study drug1
SAE at least possibly drug or drug device-related0
AE of special interest0
AE caused by study drug5
AE caused by devicesNA
AE caused by NJ tube insertionNA
Fatal AE0
PrimaryNumber of Participants With AEs, SAEs, and AEs Leading to Discontinuation During the ABT-SLV187 Treatment Period

AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.

Time frame:
From NJ placement to end of ABT-SLV187 Treatment Period (Day 21) +30 days
Reported as:
Number · participants
Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
AE4
AE at least possibly related to study drug/device3
Severe AE1
SAE1
AE leading to discontinuation of study drug1
SAE at least possiby drug or drug device-related1
AE of special interest2
AE caused by study drug3
AE caused by devices0
AE caused by NJ tube insertion1
Fatal AE0
PrimaryNumber of Participants With Potentially Clinically Significant (PCS) Hematology Results During the ABT-SLV187 Treatment Period

M=male, F=female, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant (PCS) Hematology Results During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
Low PCS Hematocrit [%]: 39.8 M / 33.4 F3
High PCS Hematocrit [%]: 51.8 M / 44.9 F0
Low PCS Hemoglobin [g/dL]: 13.5 M / 11.3 F3
High PCS Hemoglobin [g/dL]: 17.6 M / 15.2 F0
Low PCS RBC Count [*10^4/µL]: 427 M / 376 F3
High PCS RBC Count [*10^4/µL]: 570 M / 500 F0
Low PCS WBC Count [/µL]: 3900 M / 3500 F1
High PCS WBC Count [/µL]: 9800 M / 9100 F0
Low PCS Neutrophils [%]: 40.00
High PCS Neutrophils [%]: 74.00
Low PCS Lymphocytes [%]: 18.00
High PCS Lymphocytes [%]: 59.00
Low PCS Monocytes [%]: 0.00
High PCS Monocytes [%]: 8.01
Low PCS Basophils [%]: 0.00
High PCS Basophils [%]: 2.00
Low PCS Eosinophils [%]: 0.00
High PCS Eosinophils [%]: 6.00
Low PCS Platelet count [*10^4/µL]: 13.1 M / 13.0 F0
High PCS Platelet count [*10^4/µL]: 36.2 M/ 36.9 F1
Low PCS MCV [FL]: 82.7 M / 79.0 F0
High PCS MCV [FL]: 101.6 M / 100.0 F0
Low PCS MCH [Pg]: 28 M / 26.3 F0
High PCS MCH [Pg]: 34.6 M / 34.3 F0
Low PCS MCHC [%]: 31.6 M / 30.7 F1
High PCS MCHC [%]: 36.6 M / 36.6 F0
PrimaryNumber of Participants With PCS Blood Biochemistry Results During the ABT-SLV187 Treatment Period

M=male, F=female, γ-GTP=gamma-glutamyl transpeptidase.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Number of Participants With PCS Blood Biochemistry Results During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
Low PCS Blood urea nitrogen [mg/dL]: 60
High PCS Blood urea nitrogen [mg/dL]: 201
Low Creatinine [mg/dL]: 0.61 M / 0.47 F2
High Creatinine [mg/dL]: 1.04 M / 0.79 F0
Low PCS Total bilirubin [mg/dL]: 0.20
High PCS Total bilirubin [mg/dL]: 1.00
Low PCS Alanine aminotransferase [U/L]: 50
High PCS Alanine aminotransferase [U/L]: 400
Low PCS Aspartate aminotransferase [U/L]: 101
High PCS Aspartate aminotransferase [U/L]: 400
Low PCS Alkaline phosphatase [U/L]: 1150
High PCS Alkaline phosphatase [U/L]: 3591
Low PCS γ-GTP [U/L]: 00
High PCS γ-GTP [U/L]: 70 M / 30 F0
Low PCS Sodium [mEq/L]: 1361
High PCS Sodium [mEq/L]: 1470
Low PCS Potassium [mEq/L]: 3.60
High PCS Potassium [mEq/L]: 5.00
Low PCS Calcium [mg/dL]: 8.73
High PCS Calcium [mg/dL]: 10.10
Low PCS Chloride [mEq/L]: 981
High PCS Chloride [mEq/L]: 1090
Low PCS Magnesium [mg/dL]: 1.80
High PCS Magnesium [mg/dL]: 2.61
Low PCS Inorganic Phosphors [mg/dL]: 2.40
High PCS Inorganic Phosphors [mg/dL]: 4.31
Low PCS Uric acid [mg/dL]: 3.7 M / 2.5 F2
High PCS Uric acid [mg/dL]: 7 M / 7.0 F0
Low PCS Total cholesterol [mg/dL]: 1500
High PCS Total cholesterol [mg/dL]: 2192
Low PCS Total protein [g/dL]: 6.75
High PCS Total protein [g/dL]: 8.30
Low PCS Albumin [g/dL]: 4.03
High PCS Albumin [g/dL]: 5.00
Low PCS Glucose [mg/dL]: 700
High PCS Glucose [mg/dL]: 1091
Low PCS Triglycerides [mg/dL]: 501
High PCS Triglycerides [mg/dL]: 1490
Low PCS Creatine kinase [U/L]: 57 M / 32 F1
High PCS Creatine kinase [U/L]: 197 M / 180 F3
Low PCS Bicarbonate [mEq/L]: 220
High PCS Bicarbonate [mEq/L]: 290
Low PCS Lactate dehydrogenase [U/L]: 1150
High PCS Lactate dehydrogenase [U/L]: 2451
PrimaryNumber of Participants With PCS Values in Special Laboratory Parameters During the ABT-SLV187 Treatment Period

M=male, F=female

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Number of Participants With PCS Values in Special Laboratory Parameters During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
Low PCS Vitamin B6 pyridoxamine [ng/mL]: </= 0.60
Low PCS Vitamin B6 pyridoxal [ng/mL]: 6.0 M/4.0 F4
High PCS Vitamin B6 pyridoxal [ng/mL]: 40 M / 19 F1
Low PCS Vitamin B6 pyridoxine [ng/mL]: </= 3.00
Low PCS Vitamin B12 [pg/mL]: 1801
High PCS Vitamin B12 [pg/mL]: 9140
Low PCS Homocysteine [nmol/mL]: 3.70
High PCS Homocysteine [nmol/mL]: 13.54
Low PCS Folic acid [ng/mL]: < 3.11
SecondaryMean Change From Baseline to the End of Treatment in Percentage of Ratings in the "OFF" and "Dyskinesia" States on the TRS I and the "Normal," "OFF," and "Dyskinesia" States on the TRS II

Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and TRS under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia for TRS I, with the addition of Tremor at Rest and Postural Stability for TRS II. The average of the 3 neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia"), the "Off" state ("moderate OFF" to "severe OFF"), and the "Dyskinesia" state ("ON with moderate dyskinesia" to "ON with severe dyskinesia") on the TRS I or II.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · percentage of ratings
Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "OFF" and "Dyskinesia" States on the TRS I and the "Normal," "OFF," and "Dyskinesia" States on the TRS II
percentage of ratingsLevodopa-carbidopa Intestinal Gel
TRS I "OFF" state-15.33 ± 13.04
TRS I "Dyskinesia" state0.00 ± 4.71
TRS II "Normal" state14.67 ± 18.65
TRS II "OFF" state-15.33 ± 18.65
TRS II "Dyskinesia" state0.67 ± 1.49
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.058
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 1.000
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.153
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.140
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.374
SecondaryChange From Baseline to the End of Treatment in Parkinson's Disease Diary Assessment

For each half hour period during 3 consecutive days prior to each assessment of the diary, participants (and/or their caregivers) entered into a diary whether they were asleep, in the ON motor state or in the OFF motor state in the following 5 grades: asleep, OFF, ON (no dyskinesia \[D\]), ON with non-troublesome dyskinesia (NTD), ON with troublesome dyskinesia (TD). ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug. Dyskinetic time is time with involuntary muscle movement. The ON or OFF times were calculated as the average of 3 daily times from the diaries. w/o = without, w/ = with

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · hours
Change From Baseline to the End of Treatment in Parkinson's Disease Diary Assessment
hoursLevodopa-carbidopa Intestinal Gel
Daily OFF time-1.02 ± 3.73
Daily ON time w/o D + time w/ NTD0.76 ± 3.61
Daily ON time w/o D + time w/ NTD + time w/ TD1.02 ± 3.73
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.574
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.661
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.574
SecondaryBaseline and Endpoint (End of Treatment) Video Scoring of Unified Parkinson's Disease Rating Scale (UPDRS) Items and Dyskinesia

Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the video under blinded conditions using the following assessments: Tremor at Rest (UPDRS item #20), Finger Taps (UPDRS #23), Rapid Alternating Movement of Hands (UPDRS #25), Arising from Chair (UPDRS #27), Gait (UPDRS #29), Postural Stability (UPDRS #30), Body Bradykinesia and Hypokinesia (UPDRS #31), and Dyskinesia (evaluated with the Goetz Dyskinesia Rating Scale). The UPDRS score is the sum of the answers to individual questions, each of which are measured on a 5-point scale (0-4), with higher scores associated with more disability. The Goetz Dyskinesia Rating Scale is a 5-point scale of the severity of dyskinesias, from 0 (absent) to 4 (violent dyskinesias).

Time frame:
Baseline (Day -1), Endpoint (Day 21)
Reported as:
Mean · units on a scale
Baseline and Endpoint (End of Treatment) Video Scoring of Unified Parkinson's Disease Rating Scale (UPDRS) Items and Dyskinesia
units on a scaleLevodopa-carbidopa Intestinal Gel
Tremor at rest, Baseline0.00 ± 0.00
Tremor at rest, Endpoint0.00 ± 0.00
Finger taps, Baseline0.40 ± 0.55
Finger taps, Endpoint0.40 ± 0.55
Rapid alternating movement of hands, Baseline1.00 ± 0.00
Rapid alternating movement of hands, Endpoint0.60 ± 0.55
Arising from chair, Baseline0.10 ± 0.22
Arising from chair, Endpoint0.00 ± 0.00
Gait, Baseline0.60 ± 0.55
Gait, Endpoint0.60 ± 0.55
Postural stability, Baseline1.60 ± 0.55
Postural stability, Endpoint1.10 ± 0.89
Body bradykinesia and hypokinesia, Baseline1.00 ± 0.00
Body bradykinesia and hypokinesia, Endpoint0.80 ± 0.27
Dyskinesia, Baseline0.40 ± 0.55
Dyskinesia, Baseline0.90 ± 0.55
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 0.500
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 1.000
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 0.250
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 0.500
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 0.250
SecondaryMean Change From Baseline to the End of Treatment in UPDRS Total Scores and Subscores

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score ranges from 0-176, with 176 representing the worst (total) disability, and 0 no disability. The Part I Score is the sum of the answers to the 4 questions related to Mentation, Behavior and Mood, and ranges from 0-16. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. The Part IV Score is the sum of the answers to the 11 questions related to Complications of Therapy, and ranges from 0-23. The Part IV dyskinesia subscore ranges from 0-12. For each part of the UPDRS, higher scores are associated with more disability.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · units on a scale
Mean Change From Baseline to the End of Treatment in UPDRS Total Scores and Subscores
units on a scaleLevodopa-carbidopa Intestinal Gel
Total score-0.60 ± 7.70
Part I0.20 ± 0.45
Part II0.60 ± 4.93
Part II (Off-time)-2.20 ± 6.54
Part III-1.40 ± 4.56
Part IV subscore of dyskinesia2.20 ± 2.39
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.870
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.374
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.799
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.493
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.530
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.108
SecondaryChange From Baseline to the End of Treatment in the Japanese Version of Parkinson's Disease Questionnaire 39 (PDQ-39) Total Score and Domain Scores

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients, including Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort, as well as a Summary Index Total Score. Scores for each are on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · units on a scale
Change From Baseline to the End of Treatment in the Japanese Version of Parkinson's Disease Questionnaire 39 (PDQ-39) Total Score and Domain Scores
units on a scaleLevodopa-carbidopa Intestinal Gel
Total score1.26 ± 5.48
Domain: Mobility10.00 ± 20.16
Domain: Activities of daily living-0.83 ± 14.25
Domain: Emotional well-being-8.33 ± 12.84
Domain: Stigma1.25 ± 10.27
Domain: Social support-5.00 ± 6.85
Domain: Cognition-5.00 ± 13.55
Domain: Communication1.67 ± 20.75
Domain: Bodily discomfort8.33 ± 30.62
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.636
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.329
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.902
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.220
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.799
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.178
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.456
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.866
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.576
SecondaryModified Hoehn and Yahr Staging at Baseline and End of Treatment

Participant's ON and OFF states staged according to the Modified Hoehn and Yahr criteria, an 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Median · units on a scale
Modified Hoehn and Yahr Staging at Baseline and End of Treatment
units on a scaleLevodopa-carbidopa Intestinal Gel
ON state staging, Baseline2.5 (2.5 to 3)
ON state staging, Endpoint3.0 (2 to 3)
OFF state staging, Baseline4.0 (4 to 4)
OFF state staging, Endpoint4.0 (2 to 4)
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 1.000
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 1.000
SecondarySchwab and England Activities of Daily Living Scale at Baseline and End of Treatment

The Schwab and England scale was used to rate the subject's activities of daily living by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%).

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Median · units on a scale
Schwab and England Activities of Daily Living Scale at Baseline and End of Treatment
units on a scaleLevodopa-carbidopa Intestinal Gel
Baseline80.0 (50 to 80)
Endpoint80.0 (70 to 90)
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Wilcoxon one-sample test · p = 0.125
SecondaryClinical Global Impression - Severity (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Baseline and End of Treatment

The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, and among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Clinical Global Impression - Severity (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Baseline and End of Treatment
participantsLevodopa-carbidopa Intestinal Gel
CGI-S, Baseline: Normal0
CGI-S, Baseline: Borderline ill0
CGI-S, Baseline: Mildly ill0
CGI-S, Baseline: Moderately ill2
CGI-S, Baseline: Markedly ill3
CGI-S, Baseline: Severely ill0
CGI-S, Baseline: Among the most extremely ill0
CGI-S, Endpoint: Normal1
CGI-S, Endpoint: Borderline ill0
CGI-S, Endpoint: Mildly ill0
CGI-S, Endpoint: Moderately ill3
CGI-S, Endpoint: Markedly ill1
CGI-S, Endpoint: Severely ill0
CGI-S, Endpoint: Among the most extremely ill0
CGI-I: Very much improved1
CGI-I: Much improved3
CGI-I: Minimally improved1
CGI-I: No change0
CGI-I: Minimally worse0
CGI-I: Much worse0
CGI-I: Very much worse0
PrimaryNumber of Participants With Potentially Clinically Significant Urinalysis Results During the ABT-SLV187 Treatment Period
Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Urinalysis Results During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
Low PCS Specific gravity: 1.0020
High PCS Specific gravity: 1.0300
Low PCS pH: 4.50
High PCS pH: 8.01
High PCS Protein: > trace0
High PCS Glucose: > trace0
High PCS Occult blood: > negative0
High PCS Ketone: > negative0
PrimaryNumber of Participants With Potentially Clinically Significant (PCS) Vital Signs Results During the ABT-SLV187 Treatment Period

↓=decrease, ↑=increase, BL=baseline, temp.=temperature, SBP=systolic blood pressure, Sup.=supine, Sta.=standing, DBP=diastolic blood pressure.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant (PCS) Vital Signs Results During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
Low PCS Weight [kg]: ≥7% ↓ from BL0
High PCS Weight [kg]: ≥7% ↑ from BL0
High PCS Body temp. [⁰C]: ≥38.8 and ≥1.1 ↑ from BL0
Low PCS SBP Sup. [mmHg]: ≤90 and >30 ↓ from BL0
High PCS SBP Sup. [mmHg]: ≥180 and >40 ↑ from BL0
Low PCS SBP Sta. [mmHg]: ≤90 and >30 ↓ from BL1
High PCS SBP Sta. [mmHg]: ≥180 and >40 ↑ from BL0
Low PCS SBP Orthostatic [mmHg]: ↓ of ≥30 in SBP1
Low PCS DBP Sup. [mmHg]: ≤50 and >30 ↓ from BL0
High PCS DBP Sup. [mmHg]: ≥105 and >30 ↑ from BL0
Low PCS DBP Sta. [mmHg]: ≤50 and >30 ↓ from BL0
High PCS DBP Sta. [mmHg]: ≥105 and >30 ↑ from BL0
Low PCS DBP Orthostatic [mmHg]: ↓ of ≥20 in DBP1
Pulse rate [bpm]: ≤50 and >30 ↓ from BL0
Pulse rate [bpm]: ≥120 and >30 ↑ from BL0
PrimaryNumber of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period

High potentially clinically significant Bazett's heart rate-corrected QT interval (QTcB) values were: 450 msec for males / 470 msec for females.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period0
PrimaryMean Change From Baseline to the End of Treatment in Percentage of Ratings in the "Normal" State on the Treatment Response Scale (TRS) I

Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and Treatment Response Scale (TRS) under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia. The average of the neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia") on the TRS I (total 10 assessments per day).

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · percentage of ratings
Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "Normal" State on the Treatment Response Scale (TRS) I
percentage of ratingsLevodopa-carbidopa Intestinal Gel
Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "Normal" State on the Treatment Response Scale (TRS) I15.33 ± 14.26
Statistical analysis
  • Levodopa-carbidopa Intestinal Gel · Paired t-test · p = 0.074
SecondaryTime to Reach Peak Plasma Concentration (Tmax) After Administration of Oral Levodopa/Carbidopa (L/C) Tablets and Intra-jejunal Administration of ABT-SLV187

Tmax of levodopa, carbidopa, and its metabolite 3-O-methyldopa (3-OMD) after administration of oral L/C tablets and intra-jejunal administration of ABT-SLV187.

Time frame:
Baseline (Day -1): pre-dose; 15, 30, 45, 60 mins post-morning dose; every 30 mins thereafter for 12 hrs. Day 21: pre-dose; 15, 30, 45, 60 mins post-infusion; every 30 mins from hrs 1 to 12 post-infusion; every 2 hrs from 12 to 16 hrs post-infusion.
Reported as:
Mean · hours
Time to Reach Peak Plasma Concentration (Tmax) After Administration of Oral Levodopa/Carbidopa (L/C) Tablets and Intra-jejunal Administration of ABT-SLV187
hoursOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
Levodopa3.0 ± 3.51.0 ± 0.50
Carbidopa7.8 ± 2.84.5 ± 4.2
3-OMD11 ± 0.7611 ± 0.79
SecondaryPeak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), Trough Plasma Concentration (Cmin), and Cmin Within 2 and 12 Hours (Cmin [2-12 Hours]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

Cmax, Cavg, Cmin, and Cmin (2-12 hours) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). Cmin values for levodopa and carbidopa during the 16 hours of infusion were observed either at time 0 or 15 min after start of the infusion and were a result of drug washout prior to establishment of infusion.

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · µg/mL
Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), Trough Plasma Concentration (Cmin), and Cmin Within 2 and 12 Hours (Cmin [2-12 Hours]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
µg/mLOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
Cmax: Levodopa5.96 ± 0.774.38 ± 1.15
Cmax: Carbidopa0.128 ± 0.030.273 ± 0.07
Cmax: 3-OMD9.27 ± 2.1711.7 ± 1.25
Cavg: Levodopa2.37 ± 0.262.87 ± 0.66
Cavg: Carbidopa0.079 ± 0.020.172 ± 0.04
Cavg: 3-OMD7.36 ± 1.939.80 ± 1.23
Cmin: Levodopa0.268 ± 0.430.061 ± 0.03
Cmin: Carbidopa0.014 ± 0.020.016 ± 0.01
Cmin: 3-OMD5.67 ± 1.607.78 ± 0.63
Cmin (2-12 hours): Levodopa0.734 ± 0.432.38 ± 0.77
Cmin (2-12 hours):Carbidopa0.050 ± 0.020.130 ± 0.04
Cmin (2-12 hours): 3-OMD5.72 ± 1.538.14 ± 0.94
SecondaryThe Area Under the Concentrations-time Curve From 0 to 12 and 0 to 16 Hours (AUC0-12, AUC0-16) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

AUC0-12 and AUC0-16 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · µg*h/mL
The Area Under the Concentrations-time Curve From 0 to 12 and 0 to 16 Hours (AUC0-12, AUC0-16) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
µg*h/mLOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
AUC0-12: Levodopa28.4 ± 3.0834.4 ± 7.95
AUC0-12: Carbidopa0.94 ± 0.182.07 ± 0.52
AUC0-12: 3-OMD88.3 ± 23.1118 ± 14.7
AUC0-16: LevodopaNA ± NA46.7 ± 10.7
AUC0-16: CarbidopaNA ± NA2.80 ± 0.666
AUC0-16: 3-OMDNA ± NA165 ± 21.2
SecondaryAUC0-12/Dose0-12, AUC0-16/Dose0-16 After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

AUC0-12/Dose0-12 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). AUC0-16/Dose0-16 of levodopa, carbidopa, and 3-OMD after administration of intra-jejunal administration of ABT-SLV187 (Day 21).

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · µg*h/mL/mg
AUC0-12/Dose0-12, AUC0-16/Dose0-16 After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
µg*h/mL/mgOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
AUC0-12/Dose0-12: Levodopa0.036 ± 0.0080.032 ± 0.006
AUC0-12/Dose0-12: Carbidopa0.012 ± 0.0030.008 ± 0.001
AUC0-12/Dose0-12: 3-OMD0.112 ± 0.0290.113 ± 0.022
AUC0-16/Dose0-16: LevodopaNA ± NA0.035 ± 0.007
AUC0-16/Dose0-16: CarbidopaNA ± NA0.008 ± 0.001
AUC0-16/Dose0-16: 3-OMDNA ± NA0.125 ± 0.025
SecondaryDegree of Fluctuation (2-12 Hours) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

Degree of Fluctuation (calculated as \[Cmax - Cmin\] / Cavg)) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · ratio
Degree of Fluctuation (2-12 Hours) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
ratioOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
Levodopa2.1 ± 0.590.38 ± 0.16
Carbidopa0.97 ± 0.200.78 ± 0.25
3-OMD0.48 ± 0.100.35 ± 0.07
SecondaryRatio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

M/P (AUC0-12) after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).

Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Mean · ratio
Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
ratioOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV1873.11 ± 0.713.53 ± 0.70
SecondaryNumber of Participants With Product Quality Complaints (PQC) During the ABT-SLV187 Treatment Period
Time frame:
Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Reported as:
Number · participants
Number of Participants With Product Quality Complaints (PQC) During the ABT-SLV187 Treatment Period
participantsLevodopa-carbidopa Intestinal Gel
Any PQC2
Any PQC related to an AE0
Any serious PQC0
Any PQC leading to discontinuation of study drug0
Any PQC by pump0
Any PQC by NJ-tube insertion2
Any PQC by adapter0
Any PQC by cassettes1
Without any PQCs4

Adverse events

Collected over AEs: from the time of first study drug administration in the Run-in Period to 30 days following completion or discontinuation of study drug administration (up to 79 days). SAEs from the time of Screening (up to 93 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Levodopa-carbidopa Tablets—0/8 (0%)7/8 (87.5%)
Levodopa-carbidopa Intestinal Gel—1/6 (16.7%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
DelusionPsychiatric disorders0/81/6
Hallucination, auditoryPsychiatric disorders0/81/6
Somatic hallucinationPsychiatric disorders0/81/6
Most frequent other events
Showing 10 of 31
Most frequent other events
EventOral Levodopa-carbidopa TabletsLevodopa-carbidopa Intestinal Gel
ConstipationGastrointestinal disorders3/80/6
InsomniaPsychiatric disorders3/80/6
FallInjury, poisoning and procedural complications1/82/6
DyskinesiaNervous system disorders0/82/6
NauseaGastrointestinal disorders2/81/6
AnaemiaBlood and lymphatic system disorders0/81/6
StomatitisGastrointestinal disorders0/81/6
VomitingGastrointestinal disorders0/81/6
Intentional medical device removal by patientGeneral disorders0/81/6
MalaiseGeneral disorders0/81/6

Baseline characteristics

full safety sample

Age, Continuous
Age, Continuous(years)Levodopa-carbidopa Intestinal Gel
Mean65.4 ± 6.19
Age, Customized
Age, Customized(participants)Levodopa-carbidopa Intestinal Gel
< 65 years4
>/= 65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Levodopa-carbidopa Intestinal Gel
Female2
Male6
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2011
First posted
Nov 24, 2011
Start
Oct 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Mar 15, 2016
Last update
Apr 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01479127
Collaborators
Abbott Japan Co.,Ltd
Responsible party
Sponsor
First posted
Nov 24, 2011
Start date
Oct 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Mar 15, 2016
Last update
Apr 21, 2016

Study contacts

Yukihiro Kumamoto, MS
study director · AbbVie Japan Co., Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion